Loading...
Docoh

Precision Biosciences (DTIL)

51 patents

Page 2 of 3
Utility
Dystrophin Gene Exon Deletion Using Engineered Nucleases
20 May 21
The invention relates to the field of molecular biology and recombinant nucleic acid technology.
Derek Jantz, James Jefferson Smith, Michael G. Nicholson
Filed: 25 Sep 20
Utility
Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)
18 May 21
The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein.
Aaron Martin, Jon E. Chatterton, Michelle Brenda Pires
Filed: 22 Jun 20
Utility
Recognition Sequences for I-crei-derived Meganucleases and Uses Thereof
6 May 21
Methods of cleaving double-stranded DNA that can be recognized and cleaved by a rationally-designed, I-CreI-derived meganuclease are provided.
Derek Jantz, James Jefferson Smith
Filed: 7 Oct 20
Utility
Optimized Engineered Nucleases Having Specificity for the Human T Cell Receptor Alpha Constant Region Gene
22 Apr 21
The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within the first exon of the human T cell receptor (TCR) alpha constant region gene.
James Jefferson Smith, Janel Lape, Hui Li, Jochen Genschel
Filed: 11 Apr 19
Utility
Engineered Meganucleases with Recognition Sequences Found In the Human T Cell Receptor Alpha Constant Region Gene
25 Feb 21
Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human T cell receptor alpha constant region gene.
Michael G. Nicholson, James Jefferson Smith, Derek Jantz, Victor Bartsevich, Daniel T. MacLeod, Jeyaraj Antony
Filed: 9 Sep 20
Utility
Rationally-designed Single-chain Meganucleases with Non-palindromic Recognition Sequences
25 Feb 21
Disclosed are rationally-designed, non-naturally-occurring meganucleases in which a pair of enzyme subunits having specificity for different recognition sequence half-sites are joined into a single polypeptide to form a functional heterodimer with a non-palindromic recognition sequence.
James Jefferson Smith, Derek Jantz
Filed: 23 Oct 20
Utility
Engineered Meganucleases with Recognition Sequences Found In the Human BETA-2 Microglobulin Gene
4 Feb 21
Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human beta-2 microglobulin gene.
Victor Bartsevich, Christina Pham, Aaron Martin, Derek Jantz, James Jefferson Smith, Michael G. Nicholson
Filed: 19 Oct 20
Utility
Treatment of Retinitis Pigmentosa Using Engineered Meganucleases
6 Jan 21
Disclosed are recombinant meganucleases engineered to recognize and cleave recognition sequences present in a mutant RHO P23H allele.
Victor Bartsevich, Derek Jantz, James Jefferson Smith, Michael G. Nicholson
Filed: 16 Jul 20
Utility
Co-stimulatory Domains for Use In Genetically-modified Cells
23 Dec 20
The present disclosure provides novel co-stimulatory domains useful in genetically-modified cells to promote cell proliferation and/or promote cytokine secretion after antigen recognition.
Derek Jantz, Aaron Martin, Daniel T. MacLeod
Filed: 8 Sep 20
Utility
Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome
30 Nov 20
The present invention encompasses engineered meganucleases which recognize and cleave a recognition sequence within an open reading frame (ORF) of the genome of at least two genotypes of the Hepatitis B virus (HBV).
Derek Jantz, James Jefferson Smith
Filed: 16 Apr 20
Utility
Genetically-modified Immune Cells Comprising a Microrna-adapted Shrna (Shrnamir)
25 Nov 20
The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein.
Aaron Martin, Jon E. Chatterton, Michelle Brenda Pires
Filed: 21 Jun 20
Utility
Nucleic Acid Molecules Encoding an Engineered Antigen Receptor and an Inhibitory Nucleic Acid Molecule and Methods of Use Thereof
28 Oct 20
The present disclosure provides nucleic acid molecules encoding an engineered antigen receptor, such as a chimeric antigen receptor or exogenous T cell receptor, and an inhibitory nucleic acid molecule, such as an RNA interference molecule.
Joann Hux, Aaron Martin, Derek Jantz, Clayton Beard
Filed: 12 Jul 20
Utility
Engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene
12 Oct 20
Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human T cell receptor alpha constant region gene.
Michael G. Nicholson, James Jefferson Smith, Derek Jantz, Victor Bartsevich, Daniel T. MacLeod, Jeyaraj Antony
Filed: 4 Oct 16
Utility
Co-stimulatory domains for use in genetically-modified cells
12 Oct 20
The present disclosure provides novel co-stimulatory domains useful in genetically-modified cells to promote cell proliferation and/or promote cytokine secretion after antigen recognition.
Derek Jantz, Aaron Martin, Daniel T. MacLeod
Filed: 10 Oct 19
Utility
Self-limiting Viral Vectors Encoding Nucleases
30 Sep 20
Disclosed herein are viral vectors for use in recombinant molecular biology techniques.
Derek Jantz, James Jefferson Smith, Michael G. Nicholson
Filed: 13 Apr 20
Utility
Engineered Nucleases That Target Human and Canine Factor VIII Genes As a Treatment for Hemophilia a
23 Sep 20
The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within the int22h-1 sequence of a Factor VIII gene.
Armin Hekele, Clayton Beard, Derek Jantz, James Jefferson Smith, Victor Bartsevich
Filed: 31 Oct 18
Utility
Treatment of retinitis pigmentosa using engineered meganucleases
31 Aug 20
Disclosed are recombinant meganucleases engineered to recognize and cleave recognition sequences present in a mutant RHO P23H allele.
Victor Bartsevich, Derek Jantz, James Jefferson Smith, Michael G. Nicholson
Filed: 13 Feb 20
Utility
Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
17 Aug 20
The present disclosure provides nucleic acid molecules encoding an engineered antigen receptor, such as a chimeric antigen receptor or exogenous T cell receptor, and an inhibitory nucleic acid molecule, such as an RNA interference molecule.
Joann Hux, Aaron Martin, Derek Jantz, Clayton Beard
Filed: 7 Nov 19
Utility
Modified Epidermal Growth Factor Receptor Peptides for Use In Genetically-modified Cells
29 Jul 20
The present disclosure provides modified EGFR peptides useful in genetically-modified cells to allow for selection and enrichment of those cells expressing the modified EGFR peptide.
Derek Jantz, James Jefferson Smith, Daniel T. MacLeod
Filed: 2 Oct 18
Utility
Engineered Meganucleases Specific for Recognition Sequences In the Hepatitis B Virus Genome
29 Jul 20
The present invention encompasses engineered meganucleases which recognize and cleave a recognition sequence within an open reading frame (ORF) of the genome of at least two genotypes of the Hepatitis B virus (HBV).
Derek Jantz, James Jefferson Smith
Filed: 16 Apr 20
Patents are sorted by USPTO publication date, most recent first